Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL RSV vaccine study in infants and toddlers
2023-505762-29-00Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2024
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, single-blind trial of RSVt vaccine in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Sanofi. Primary endpoint: Occurrence of lower respiratory tract disease during RSV Season 1 associated with any RT-PCR confirmed RSV strain more than 21 days after dose 2. Started May 2024; status: completed.
02
Drugs
RSVt vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2023-505762-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505762-29-00.